Thoratec Adds Sales Reps For Launch Of HeartMate II As Destination Therapy
This article was originally published in The Gray Sheet
Executive Summary
Thoratec is beefing up its sales force to emphasize physician referrals now that FDA has approved its HeartMate II ventricular assist device as a "destination" therapy for patients who are not candidates for a heart transplant
You may also be interested in...
Dick Cheney Discusses Experience With HeartMate II Device
Thoratec’s miniature rotary blood pump LVAD is something Dick Cheney has “gotten used to living with,” the former U.S. vice president said Oct. 5 at the Cleveland Clinic’s annual Medical Innovations Summit in Cleveland, during an interview with ABC News anchor Bob Woodruff.
Dick Cheney Discusses Experience With HeartMate II Device
Thoratec’s miniature rotary blood pump LVAD is something Dick Cheney has “gotten used to living with,” the former U.S. vice president said Oct. 5 at the Cleveland Clinic’s annual Medical Innovations Summit in Cleveland, during an interview with ABC News anchor Bob Woodruff.
Thoretec Pipeline: HeartMate III Fully Magnetic LVAD Trial Set For 2012
Thoratec plans to start a clinical trial at the end of 2012 for its next-generation HeartMate III left ventricular assist device with a magnetically levitated rotor designed to help reduce the risk of pump-related clots, bleeding and strokes.